Autoimmune Diseases  >>  baminercept (BG 9924)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

6 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
baminercept (BG 9924) / Biogen
NCT00458861 / 2006-005467-26: BG9924 in Combination With Methotrexate for Participants With Active Rheumatoid Arthritis

Terminated
2b
115
US
BG9924, Placebo Comparator
Biogen
Rheumatoid Arthritis
10/08
10/08
RESPOND, NCT00664716 / 2006-005466-39: Assessment Of The Safety And Efficacy Of BG9924 In Rheumatoid Arthritis (RA) Participants

Completed
2
391
Europe, RoW
Baminercept alfa 1, BG9924, LT beta, Placebo, Baminercept alfa 2, Baminercept alfa 3, Baminercept alfa 4, Baminercept alfa 5
Biogen
Rheumatoid Arthritis
10/08
10/08
NCT00523328 / 2007-000734-38: BG9924 in Combination With Methotrexate Extension of Study 104RA203 (NCT 00458861)

Terminated
2
72
US, Canada, Europe
BG9924, LTbeta
Biogen
Rheumatoid Arthritis
10/08
10/08
RESPOND-EXT, NCT00664573 / 2007-000733-19: 104RA204 Assessment of the Safety and Efficacy of BG9924 in Rheumatoid Arthritis (RA) Participants

Terminated
2
339
Europe, RoW
Baminercept alfa (BG9924), BG9924, Baminercept alfa, LT beta
Biogen
Rheumatoid Arthritis
10/08
10/08
NCT01552681: Baminercept, a Lymphotoxin-Beta Receptor Fusion Protein, for Treatment of Sjögren's Syndrome

Terminated
2
52
US
Baminercept, lymphotoxin-beta receptor-immunoglobulin fusion protein, Placebo, baminercept placebo
National Institute of Allergy and Infectious Diseases (NIAID), Autoimmunity Centers of Excellence, Biogen
Primary Sjögren's Syndrome
01/15
06/15
NCT01181089: Dose Escalation Study to Evaluate the Penetration and Pharmacodynamic Effects of Baminercept in the Cerebrospinal Fluid (CSF)and Safety in Subjects With Secondary Progressive Multiple Sclerosis (SPMS)

Withdrawn
1/2
0
Europe
Placebo, Baminercept
Biogen
Secondary Progressive Multiple Sclerosis
 
 

Download Options